海正藥業(600267.SH):2022年度扣非淨利潤預增34.59%到63.60%
格隆匯1月30日丨海正藥業(600267.SH)公佈,預計2022年年度實現歸屬於上市公司股東的淨利潤為4.45億元到5.4億元,與上年同期相比,將增加-4189萬元到5311萬元,同比增長-8.60%到10.91%。
預計2022年年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤為2.83億元到3.44億元,與上年同期相比,將增加7273萬元到13373萬元,同比增長34.59%到63.60%。
預計2022全年歸屬於上市公司股東扣除非經常性損益的淨利潤變化的主要原因是:(一)輝瑞產品地產化按計劃順利推進,製劑產能利用率提升,相關產品盈利能力增強;(二)公司經營性現金流持續向好,有息負債規模進一步下降,融資成本降低,財務費用同比下降;(三)公司資產管理及週轉效率提升,信用減值損失及存貨跌價損失減少;(四)全額計提對浙江導明醫藥科技有限公司(“導明醫藥”)的長期股權投資減值準備,導致長期資產減值損失增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.